



Contributors Participating In Society

6.1 ACCESS TO HEALTHCARE
MANAGEMENT

6.2 CARING FOR PATIENT
JOURNEYS, ENHANCING
HEALTH OUTCOMES

6.3 GLOBAL LOCALIZATION
EMPOWERMENT AND
MEDICAL ADVANCEMENT

6.4 PHILANTHROPIC
ACTIVITIES

Chapter Highlights

**Besremi.com/
What's Next PV**

U.S. Patient Education
Support Platform

6,200+

BESREMi® cumulative
global patients usage
since launch

MPN

Taiwan Patient Education
Support Platform "Good
Medicine, Close to the Marro"

5_{groups}

Support international
educational activities for
North American MPN
patient groups

NCCN

BESREMi® upgraded in
the U.S. NCCN Treatment
Guidelines to PV2A category
preferred drug for patients

No.1

Assisted Chiayi Chang Gung
in establishing the first MPN
treatment center and the
Taiwan Myeloproliferative
Neoplasms Care Association
(TMPNA)

3

Sponsors biodiversity,
health, and cultural social
welfare initiatives, reducing
carbon emissions by 18,841
kilograms of CO₂e.

1,332_{patients}

Global cumulative clinical
trial patient usage

700+_{participants}

From 17 health education
events hosted by Panco

43_{patients}

Patients benefiting from
compassionate use therapy

3_{events}

Taiwan participates
in local community
empowerment activities

PharmaEssentia tirelessly commits to new drug development and through its Access of Medicine strategy plan, continuously promotes the acquisition of new drugs by patients worldwide. This enhances 'accessibility', ensures 'affordability', and improves 'availability'. These are our core philosophies and commitments. We follow the framework of the [2024 Access to Medicine Index](#) to formulate the group's strategic guidelines, solely to address unmet medical needs.



6.1 Access to Healthcare Management

Materiality Assessment

1,332patients

Global cumulative clinical trial patient usage

PharmaEssentia follows the framework of the 2024 Access to Medicine Index (ATMI). Under good access to healthcare governance, the company provides product development rooted in scientific innovation. By increasing medicine accessibility, accelerating the promotion of drug certification acquisition, and market distribution, PharmaEssentia helps more MPN patients obtain better treatment with Besremi, thereby improving their quality of life.

Materiality Assessment

Access to Healthcare

Impact Assessment

The core mission of the biotechnology industry is to promote human health and well-being. PharmaEssentia focuses on patient-centric care, achieving unmet patient needs through research and innovation. Before products are marketed, compassionate use therapies and clinical trial participation opportunities are provided; after marketing, the company accelerates drug certification in different markets through subsidiaries and strategic partners, enhancing the accessibility and equitable availability of medications.

Management Policies and Commitments

We are committed to providing high-quality medications to more patients whose medical needs are currently unmet. Through innovative research and development efforts, and by accelerating drug certification with market supply chain partners, we can meet the needs of more patients requiring solutions. Additionally, we are considering how to implement reasonable pricing strategies to reduce the burden of healthcare costs, demonstrating the cost-effectiveness of Besremi through cost analysis.

Governance Structure

- Taiwan headquarters along with the marketing departments and medical affairs teams of subsidiaries.
- Materiality Assessment: Managed and integrated by the members of the Access to Healthcare team from the Center for Sustainable Development.

Management Actions

Research and Development	Clinical Trial Participation	Compassionate Use Therapy	Marketing Authorization
Beyond MPN, PharmaEssentia is also investing in PEG-IL-2 technology for the treatment of inflammatory and immune diseases; and through external collaborations, jointly developing TCRT cell therapies.	In 2023, global clinical trials (multi-country, multi-ethnic) added 453 participants, bringing the total to 1,332 patients.	In 2023, a total of 43 patients received compassionate use therapy.	Obtained drug licensing in over 40+ countries.

Indicators and Goals

- In accordance with the spirit of the Access to healthcare guidelines, we use (1) the number of products developed/clinical trial participants, (2) the number of patients using Besremi, and (3) the timing of drug approvals in various countries as indicators to demonstrate how the company serves more unmet medical needs.

Practices to Ensure Effective Actions

- Continuously advancing milestones for various programs, including drug approvals, equitable access to healthcare strategies, and outcomes.
- Improving the affordability of new drugs: fair and reasonable pricing, pricing policies, drug delivery, and drug donations.

Performance in 2023

- Scientific innovation in product development: In 2023, global R&D expenses reached NT\$2.22 billion, a 55.5% increase from the previous year, and marketing expenses amounted to approximately NT\$2.13 billion, a 38.2% increase from last year. PharmaEssentia has recently accelerated the development of BESREMi® for various indications, in collaboration with partners for new drug development and expansion into new therapeutic areas, with four new indications currently under trial; additionally, six new drugs and drug combinations are being rapidly developed.
- Number of patients using the medication: In 2023, over 6,200 patients benefited from Besremi.
- Beneficiaries of compassionate use therapy: 43 patients.
- Drug approvals: Obtained in over 40 countries.

43patients

Patients benefiting from compassionate use therapy

1. Committed to providing high-quality medicines to more patients whose medical needs are currently unmet.

Compassionate Use Therapy

For regions where the drug has not yet been approved and for patients who do not qualify for clinical trials but are in severe or life-threatening situations due to MPN, PharmaEssentia conducts internal reviews and complies with regulations and ethics committees to provide compassionate use therapy to eligible patients.

Mechanisms and Progress of Compassionate Use Therapy

Operating Mechanisms


PharmaEssentia has established a standard operating procedure (PEC-MA-SOP-001) to manage the provision and execution of medications under compassionate use. As of the end of 2023, 43 patients have utilized this program.

	Type of Donated Medications	Indications	Cumulative Number of Benefiting Patients
2020	P1101	<ul style="list-style-type: none">MPN (PV, ET, MF)	38
2021	P1101	<ul style="list-style-type: none">Taiwan : MPN (PV, ET, MF)South Korean : ECD	40
2022	P1101	<ul style="list-style-type: none">Taiwan : MPN (PV, ET, MF)South Korea : ECD	40
2023	P1101	<ul style="list-style-type: none">Taiwan : MPN (PV, ET, MF), EHESingapore and Malaysia : PV	43

Note: For content related to clinical trials, please refer to Section 3.1, New Drug Research and Innovation Management.

Accelerating Drug Registration

BESREMi® has obtained marketing authorization in over 40 countries globally since its first drug license in 2018. This includes multiple European countries, as well as the United States, Japan, South Korea, Israel, and Taiwan where it is already on the market; drug licenses are currently being applied for in China, Singapore, and Malaysia. Through the establishment of subsidiaries and partnerships with strategic partners, PharmaEssentia continues to expand its global market share, providing new options for the treatment of rare diseases and reducing the burden of such treatments.



Product Delivery

Product delivery is equally important under the premise of access to healthcare; given the different regulations on drug packaging and labeling in various countries, PharmaEssentia collaborates with local stakeholders. In countries like the USA, Germany, and Japan, PharmaEssentia has signed outsourcing manufacturing contracts with local manufacturers who comply with GMP standards to enhance the smooth delivery of products. Additionally, measures are taken to combat counterfeiting. (For more details, see [3.4 Sustainable Supply Chain Management](#)).

Product Donation

Given that Besremi (P1101) can be applied in multiple disease areas, we actively collaborate with governments and the academic community to make an impact. During the severe COVID-19 pandemic, considering patient needs, PharmaEssentia donated medication to the Health and Welfare Department’s Shuang Ho Hospital for clinical use in treating mild to moderate COVID-19 patients. Out of 22 patients, 21 successfully recovered and were discharged after their test results changed from positive to negative. Based on this success, PharmaEssentia invited National Taiwan University Hospital to lead a Phase III multicenter clinical trial of P1101 for treating COVID-19, aimed at providing treatment options for mild to moderate cases. Although the pandemic subsided and the trial was not completed, PharmaEssentia will continue to adhere to its patient-centered philosophy and spirit, investing in research and collaborating with medical professionals to provide drug donations for independent clinical research based on clinical needs, accelerating the expansion of the drug’s potential benefits to help more patients in need.

Focusing on patient needs, providing comprehensive support

- **Patient Support SOURCE Program:** Applicable to patients currently using BESREMi® prescription medication. This program provides comprehensive support, from insurance information and self-pay discount programs to medication guidance and ongoing medication ordering processes. It aims to offer more convenience to patients who might not use the medication due to insurance payment delays or insufficient insurance coverage, including providing free medication for uninsured or underinsured patients. The goal is to ensure a stable supply of PharmaEssentia medications to patients, reducing their financial burden.



- In Japan, beginning in 2024, a patient support program will be established, including a website, professional medical education, and customer service centers. This program will also cover insurance and self-pay discount programs to medication guidance, assisting patients in reducing their out-of-pocket financial burdens.



NCCN

BESREMi® upgraded in the U.S. NCCN Treatment Guidelines to PV2A category preferred drug for patient

2. Responsible Pricing Strategy, Creating Medical Value and Cost-Effectiveness

Equitable Access to Healthcare Strategy and Outcomes: Enhancing product medical efficiency

GRI 416-1 SASB HC-BP-240a.1

Providing innovative drugs with medical contributions to alleviate the burden on healthcare insurance systems and meet medical needs is a crucial goal for PharmaEssentia. The medical value of BESREMi® has been included in the guidelines of the European LeukemiaNet (ELN)^{Note 1} since 2021. Additionally, the National Comprehensive Cancer Network (NCCN)^{Note 2} has also incorporated BESREMi® into its guidelines as the preferred medication for treating adults with Polycythemia Vera (PV), regardless of previous treatments or high-risk status. We have completed a comprehensive health economic evaluation (including cost-benefit, cost-utility, and cost-effectiveness analysis) of BESREMi® upon its launch in Europe to analyze its impact on healthcare costs. We are actively collecting data to support subsequent health technology assessments, thereby certifying the medical value of BESREMi®.


Note 1: ELN is a platform of 44 countries and 220 institutions involving over 1,000 researchers and clinical personnel, aimed at integrating pioneering leukemia clinical trial groups across Europe. ELN's goal is to integrate 120 pioneering leukemia clinical trial groups in Europe, along with associated service cooperation institutions, industry, and corporate resources to promote the importance of treating leukemia.

Note 2: NCCN is a nonprofit organization in the USA, comprised of a coalition of 31 cancer centers, most of which are designated as Comprehensive Cancer Centers by the National Cancer Institute.



Improving New Drug Affordability: Fair and Reasonable Pricing SASB HC-BP-240b.2, b.3

BESREMi® is the first interferon approved by the U.S. FDA for Polycythemia Vera (PV) and has been granted orphan drug status. It is also listed as the preferred medication in the U.S. NCCN guidelines. Developing orphan drugs requires significant investment in research and financial resources. Based on the principle of accessibility, we have committed substantial resources to ensure that patients can access the necessary medication as soon as it becomes available on the market.



Responsible Pricing Strategy

PharmaEssentia prioritizes patient interests in its drug pricing, also considering factors such as research and development costs, the number of patients targeted during the patent period, competitive product pricing, expected profits, reimbursements from third-party insurance companies, and health insurance payments by regulatory authorities in different countries. Prices are then set based on each country's ability to afford medical costs, economic development, pharmaceutical costs, and referencing the ["WHO Guideline on Country Pharmaceutical Pricing Policies"](#) to establish fair and reasonable drug prices.

Evidence-Supported Reasonable Pricing

PharmaEssentia evaluates the impact of its products on medical costs using health economics assessment methods (such as cost-benefit, cost-utility, and cost-effectiveness analyses) to assess the costs associated with using Besremi versus standard therapies and other competitive innovative products. This approach has been validated in its major markets.



BESREMi has passed the HTA review in Ireland, analyzing the drug's safety, efficacy, and quality of life data, confirming it is more cost-effective compared to standard treatment options.



In the U.S. market, the U.S. subsidiary has conducted cost-effectiveness analyses from the perspective of U.S. healthcare payers, also confirming greater cost-effectiveness compared to standard treatments.



PharmaEssentia subsidiary in Japan is analyzing the cost-effectiveness of BESREMi to submit to the Japanese Ministry of Health, Labour and Welfare (MHLW) as evidence for HTA. Strengthening the treatment with Besremi offers more reasonable cost-effectiveness compared to traditional therapies and competitive products.

6.2 Caring for patient journeys, enhancing health outcomes

Patient Journey

PharmaEssentia contributes to health outcomes across various stages of the patient journey, including disease awareness and screening, MPN diagnosis confirmation and treatment, as well as comprehensive patient care post-treatment, providing holistic support.



Disease Awareness and Screening

PharmaEssentia not only continues to invest in ongoing professional education for healthcare professionals in the countries where its products are marketed but also supports healthcare professionals in conducting patient education events. Additionally, in accordance with local laws, online websites are established in the marketing countries such as:

- **WHAT'S NEXT PV:**

Serving as the main patient education website for the U.S. region, this platform helps the public understand disease-related knowledge and recognize disease risks. It aims to connect the patient community through the platform, providing comprehensive support for the body, mind, and spirit during treatment, and promoting smooth communication with medical professionals.

- **www.Besremi.com:**

Offers information for U.S. patients about medication use and treatment options.



Diagnosis and Treatment

In addition to being included in national and international treatment guidelines, PharmaEssentia conducts ongoing professional education for healthcare providers in the countries where its products are marketed. This is aimed at enhancing their understanding, diagnosis, treatment, and care of MPN. PharmaEssentia also collaborates with medical associations in the marketing countries and internationally to host seminars and continuously publish significant research findings.



In disease diagnosis and treatment, PharmaEssentia has organized numerous medical professional disease education events in global markets and published various research and development achievements in professional medical journals, enhancing breakthroughs in public health and healthcare outcomes.

Key Events for 2023:

- **2023 ASCO Annual Meeting:** Presentation of the EXCEED-ET study methodology.
- **2023 ASH Annual Meeting:** Presentation on the progress of research into Primary Myelofibrosis (PMF).
- **MPN Asia Annual Meeting:** Since 2016, PharmaEssentia has been a long-term sponsor of the MPN Asia Medical Annual Meeting, aiming to promote sustainable health and social inclusion. As of 2023, six editions have been successfully held, touring four cities in Asia, showcasing PharmaEssentia's innovative contributions and social impact in the field of rare MPN diseases, highly recognized by the external community.
- **Review by Japan's MHLW for Standard of Care (SOC):** Whether to include biomarker tracking in standard treatments to confirm the reduction in risk of deterioration and even the possibility of cure.
- **Collaboration and Academic Exchange with Associations in Taiwan:** Events with the Hematology Society of Taiwan, the Pharmacists Association, etc., to enhance physicians' knowledge of the MPN field and the effectiveness of long-acting interferon treatments.
- **Chiayi Chang Gung Memorial Hospital MPN Center:** PharmaEssentia and Chiayi Chang Gung Memorial Hospital have both been deeply involved in the MPN field for many years. In addition to promoting the importance of disease treatment through the center, they also conduct clinical research for genetic mutation testing to improve the accuracy of disease diagnosis and technology.
- **Education Training for Healthcare Providers in the USA:** The U.S. subsidiary provides sponsorships to Continuing Medical Education (CME) providers to offer more medical education, including medical conferences and on-demand educational content.



PharmaEssentia provides continuous and systematic education and training for healthcare professionals, as well as patient interaction events, to improve the overall care throughout the patient treatment journey. For example, in 2023, Panco hosted 17 seminars for healthcare professionals and patients to enhance understanding of diseases and medication treatment options, thereby enhancing professional medical knowledge. These events had a total of approximately 700+ participants.

Activity name	Target name	Purpose	Timeline (Short, Medium, Long Term)	Frequency	Benefits
MPN Asia	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge
MPN Workshop	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge
Patient Activities	Patients and Healthcare Professionals	Increase disease awareness	Medium-term	Quarterly	Enhance disease management knowledge
Regional Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Medium-term	Quarterly	Enhance professional medical knowledge
Hospital Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Short-term	Every two months	Enhance professional medical knowledge
Hematology Society Annual Conference Seminar	Healthcare Professionals	Increase understanding of the disease and medication treatment options	Long-term	Annually	Enhance professional medical knowledge

Comprehensive Patient Cycle Care

To assist in comprehensive cycle care for patients, PharmaEssentia has established patient support programs, actively supports patient education and case management, continues safety monitoring, helps reduce financial burdens for patients, and promotes complete treatment. In Taiwan, it has helped establish the [Taiwan Myeloproliferative Neoplasms Care Association \(TMPNA\)](#), and also supports the American Patient Power Foundation program and the MPN Research Foundation in the USA. Key outcomes include:

- Post-Marketing Safety Monitoring:**
PharmaEssentia continuously collects safety information for BESREMi® from all countries where it is marketed to update the Drug Safety Update Report (DSUR/PSUR) and assess the risk-benefit profile of BESREMi®. To date, there have been no incidents of non-compliance with product and service health and safety regulations.
- Establishment of the Taiwan Myeloproliferative Neoplasms Care Association (TMPNA):**
Enhances patient awareness of disease treatment.
- Establishment of MPN:**
Serves as a platform for MPN-related disease information in Taiwan, sharing new treatment knowledge and care recommendations.
- American Patient Power Foundation Program:**
Supports the treatment journey for PV patients and promotes correct treatment concepts through online digital programs, facilitating patient education, promoting doctor-patient dialogue, and enhancing public understanding.



- MPN Patient Group Assistance and International Educational Activities:**

Provides support for major North American patient-related group activities, including [MPN Research Foundation](#), [Canadian MPN Research Foundation](#), [MPN Advocacy & Education International](#), [Patient Power](#), and [PV Reporter](#). Offers online information sharing and physical events to enhance patient education and exchange of opinions, spread information about disease diagnosis, treatment goals, and disease progression, while also increasing the MPN community's understanding of the medical benefits of BESREMi.

- American MPN Research Foundation and Clinical Trial Search Engine:**

Helps establish a disease clinical trial search tool for MPNRF, providing a matching channel to assist MPN patients and their treating physicians in finding suitable clinical trials for subsequent treatment.



- Patient Case Management Support:**

- ▶ Taiwan Case Management Care: Tracks patient treatment progress and subsequent medication reactions through a project-based approach.
- ▶ U.S. Medication Adherence Tracking: If a patient discontinues medication due to adverse drug reactions, PharmaEssentia can receive discontinuation information through a specialty pharmacy database and accurately record it in the drug monitoring program for follow-up.

- Patient Support Plan: (See detail in [6.2 Caring for patient journeys, enhancing health outcomes](#))**

- Compassionate Use Program: (See detail in [6.1 Access to Medicine Management](#))**

6.3 Global Localization Empowerment and Medical Advancement

Materiality
Assessment

PharmaEssentia upholds a patient-centered philosophy, planning various actions and support programs to implement drug accessibility and meet patients' health-related needs. Starting in Taiwan, caring for MPN patients through patient education, financial and medical support, and academic exchanges, the company provides a comprehensive integrated plan that penetrates every stage of the cycle of care. In 2023, the patient education program reached over 700 healthcare professionals and patients. Looking internationally, PharmaEssentia has been a long-term sponsor of MPN Asia and actively participates in renowned international societies (such as the American Society of Hematology, ASH), vigorously presenting the latest research findings to help medical professionals understand empirical evidence and new options for treating patients. In 2023, PharmaEssentia made significant research presentations at ASH, ASCO (American Society of Clinical Oncology), and other prestigious societies and international journals.



Materiality Assessment

Doctor-Patient Relationships and Local Empowerment



Impact Assessment

PharmaEssentia adopts a patient-centered approach, enhancing healthcare professionals' knowledge about diseases, strengthening doctor-patient relationships to aid in the appropriate use of medications, and through industry empowerment, helps more patients access high-quality medications.



Management Policies and Commitments

Implement actions related to patient health, including:

- Ensuring comprehensive collection of safety data through multiple adverse event reporting channels, and legally required notifications.
- Ensuring all patients using PharmaEssentia medications are well-informed about disease characteristics, drug effects, and medication outcomes.
- Promoting disease-related knowledge, providing treatment consultation and referral services.
- Caring for patient health during treatment and providing ongoing monitoring.
- Promoting local medical care and healthcare industry empowerment to expand PharmaEssentia's social external impact.



Responsible Units

- Taiwan headquarter, all subsidiaries' marketing departments, and medical affairs teams.
- Materiality Assessment: Managed and integrated by the Access to Healthcare team within the Center for Sustainable Development.



Management Actions

- Taiwan headquarter and all branches actively participate in medical industry-related lectures, sharing knowledge to promote local empowerment.
- Panco subsidiary has set up the MPN patient education and interaction platform and has assisted the Taiwan Myeloproliferative Neoplasms Care Association in organizing World MPN Day educational seminars and the first general assembly to implement patient education support activities in Taiwan.
- The U.S. subsidiary has launched the Patient Support SOURCE program and BESREMi.com.
- The Japanese subsidiary, using the U.S. patient support program as a benchmark, has established a Japanese version of the patient support program, including websites and related support activities.



Indicators and Targets

- Number of healthcare professionals (HCPs) reached.
- Number of participants in industry sharing events.



Practices to Ensure Effective Actions

- Regular review of the annual marketing and seminar activity budgets and execution by the Taiwan headquarters and all subsidiary marketing departments and medical affairs teams.
- Regular review of the planning and execution of industry sharing events.

Performance in 2023

- Panco hosted 17 large and small seminars for healthcare professionals and patients to increase their understanding of the disease and medication options, enhancing professional medical knowledge, with a total participation of about 700+ people.
- PharmaEssentia was invited to 3 local empowerment activities.
- Provide summer internship program to nurture new talent in the industry.



Communication with Stakeholders

- Regular and irregular communications with patients/public/community/industry stakeholders in various formats including social media updates.
- Regular and irregular continuing education events for healthcare professionals



Future Planning

2024

Taiwan:

- Continuously to provide the latest educational messages through MPN.
- Continue collaborating with TMPNA to organize patient education events.
- Collaborate with Chiayi Chang Gung Memorial Hospital to provide educational support activities.

USA:

- Continue promoting the "Patient Support Program SOURCE" to serve American patients.

Japan:

- Promote patient support program plans to help patients understand diseases and reduce out of pocket expenses.

Mid-Term Goals for 2025-2027:

- Continue collaborating with patient groups in various countries to promote BESREMI® and related educational activities, strengthening the correct concepts of disease treatment.
- Continuously to enhance diverse activities and stakeholder reconciliation, reaching more local medical organizations.
- Promote patient support programs in other countries where BESREMI® is marketed to increase global coverage.
- Accelerate research and development of BESREMI® in other MPN disease areas to expand BESREMI® treatment options.
- Track international initiatives, review resources and benefits that can be invested.
- Assist Taiwan patient groups in connecting with international patient groups and share treatment experiences.

Long-Term Goals for 2030:

- Expand the establishment of comprehensive rare disease medical care and community participation in all countries where BESREMI® is marketed, enhancing the company's positive contribution and impact on the global rare disease healthcare system and the overall social industry.
- Assist Taiwan patient groups in connecting with international patient groups and share treatment experiences.

Empowerment Programs along the Value Chain GRI 413-1, 413-2

PharmaEssentia actively participates in empowerment programs and key activities at every stage of the value chain, such as establishing an innovation research center utilizing artificial intelligence for new drug development, helping the American MPN Research Foundation to establish a clinical trial search tool, setting up patient support programs in Taiwan, the USA, and Japan, and enhancing drug accessibility for financially needy patients, gradually expanding to other countries. For patients already using BESREMI, a series of health promotion activities are planned to extend their medication period and perfect the overall treatment process.

Medicine Accessibility Program

This initiative aims to assist patients experiencing financial difficulties in accessing medical resources, thereby enhancing their right to access medication.

Health Promotion

For patients already using BESREMI, comprehensive care is provided to extend the duration of medication use. This includes guidance on medication knowledge and strategies to prolong the usage period effectively.

PharmaEssentia aspires to be a pioneer driving industry growth and has always been committed to participating in community co-learning and sharing initiatives. For example, the plant manager was invited to speak at the "Innovative Pharmaceutical Industry Chain Link International Competitiveness Promotion Project" seminar to exchange practical GMP process change management, promoting industry quality enhancement and to BIO Asia-Taiwan 2023, the largest biotech exhibition in Asia and a key industry exchange platform, to discuss biotechnology techniques and trends, fostering learning and sharing in the biotechnology field. The director of the Sustainability Center was invited to the "Biomedical Products Industry Low Carbon Transformation Initiative - Green Manufacturing Technology and Carbon Reduction Practice Community" to share experiences in promoting sustainable development, fostering co-operation and symbiosis in the biotech industry, while also offering a summer internship program to cultivate new industry talent. To date, the company's operations have not caused any negative impacts on the local community.



6.4 Public Welfare Activities



3

Sponsors biodiversity, health, and cultural social welfare initiatives, reducing carbon emissions by 18,841 kilograms of CO₂e.

Since the establishment of the Sustainability Development Center, PharmaEssentia has responded to the United Nations SDG3 initiative through internal educational training and external social participation. In 2023, we contributed to society by sponsoring funds and investing human resources. The following project sponsorship details:

1

• Sponsorship of the International Jane Goodall Institute for Biodiversity Advocacy Activities



Environmental awareness starts young, beginning with elementary school students on campus, striving to inspire their passion for diverse plant conservation education. The goal is to cultivate like-minded young green leaders, encouraging everyone to take action from a young age to care for the Earth and improve the environment. In 2023, PharmaEssentia sponsored the Jane Goodall Institute with NT\$100,000, and staff from the Sustainability Development Center actually visited to help advocate for biodiversity. The activity involved four elementary schools, impacting over 152 students and teachers.

This activity not only creates a positive corporate image of the company, but also echoes the goals of the United Nations SDGs 3, 4, 13 and 15, as well as the WHO One Health Initiative and the Convention on Biological Diversity, such as promoting the conservation of plant diversity to ensure sustainable medical resources and ecosystems, educating people about the importance of plant diversity to promote sustainable use of natural resources, and protecting plant diversity to help maintain ecological balance and prevent ecosystem degradation, while promoting soil conservation and water management.



2

• Sponsor the OneSong Orchestra New Year Charity Concert for 5 consecutive years to support the promotion of local culture

In order to support enterprises to promote the development of local culture and practice the Code of Practice for Corporate Sustainable Development of Listed and OTC Companies, PharmaEssentia has sponsored the OneSong Orchestra New Year Concert for 5 consecutive years. By supporting the development of culture and arts, it can not only cultivate employees' personal body and mind, combine work and rest, balance life and workplace relationships, but also promote a new ecology of integration and common good, and shape the positive image of the company. In 2023, we sponsored about NT\$1 million for this philanthropic activity and invited the company's employees participating in the planning of the marketing department, with a total of 26 participants.

Music is an integral component of the cultural sector. Hosting music concerts and cultural events not only draws tourists and audiences but also generates economic value and job prospects, while fostering urban economic growth and cultural and social progress. Consequently, this philanthropic endeavor is in alignment with the objectives of both United Nations Sustainable Development Goals (SDGs) 8 and 11.



3

• Continuing to sponsor the Digital Humanitarian Association's Rural Elderly Health Promotion Charity Events

Adhering to our entrepreneurial mission and commitment to access to healthcare, we prioritize patients and strive to transform innovative science into medical solutions that bring shared value to patients, aiming to promote human health and well-being. We have chosen to adopt telemedicine to support regions with insufficient medical service capacity, particularly focusing on the elderly population in rural areas, which aligns with our MPN -PV service group. This initiative aims to facilitate patients' timely and equitable access to healthcare resources.

Through the Rural Telehealth Elderly Health Promotion Charity Project proposed by the Wacare team of the Digital Humanitarian Association, in the remote tribal communities of Taitung County, Taiwan, which are most lacking in medical resources, we provide diversified medical resource services such as telemedicine, health promotion applications, online LIVE courses, and consultations with medical experts through digital technology. This initiative aims to provide more comprehensive support and timely care to the elderly vulnerable groups in rural areas. In 2023, a total of NT\$450,000 was sponsored, and staff from the Sustainable Development Center visited the sponsored locations, reaching over 60 individuals. The project estimates a Social Return on Investment (SROI) of 5.438 for the current year.



太麻里
大王據點

台東失智
二館據點

東河
泰源據點

社區照顧關懷據點 雙港長照站
活動作息表

第一、二、三、四、五、六、日

時間：上午 8:00 - 12:00

內容：健康講座、運動、康樂、休閒、娛樂、交流

地點：雙港長照站

時間：上午 13:00 - 17:00

內容：健康講座、運動、康樂、休閒、娛樂、交流

地點：雙港長照站

時間：上午 18:00 - 21:00

內容：健康講座、運動、康樂、休閒、娛樂、交流

地點：雙港長照站